Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Immunobiology Research Institute |
---|---|
Information provided by: | NIH AIDS Clinical Trials Information Service |
ClinicalTrials.gov Identifier: | NCT00002050 |
Examine the ability of Timunox (thymopentin) to reduce the amount and/or frequency of virus isolation. Examine the ability of thymopentin to stimulate the immune system and alter the clinical findings in patients infected with HIV who do not yet have AIDS.
Condition | Intervention |
---|---|
HIV Infections |
Drug: Thymopentin |
Study Type: | Interventional |
Study Design: | Treatment, Double-Blind |
Official Title: | A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
Patients must have the following:
Prior Medication:
Allowed:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 30 days of study entry:
Intravenous drug abuse.
Study ID Numbers: | 015D, H87-75 |
Study First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00002050 |
Health Authority: | United States: Food and Drug Administration |
Semen Thymopentin Leukocytes, Mononuclear AIDS-Related Complex |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Thymopentin Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome AIDS-Related Complex Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Immunologic Factors Immune System Diseases Physiological Effects of Drugs |
Adjuvants, Immunologic Lentivirus Infections Infection Pharmacologic Actions |